Psoriasis Hastalarında Biyolojik Tedavinin Sistemik İnflamatuvar Belirteçler ve Plateletcrit Üzerine Etkisi

Yıl 2016, Cilt: 43 Sayı: 4, 477 - 476, 25.12.2016

Bengü Çevirgen Cemil Hatice Ataş

Öz

Amaç: Psoriasis keratinositlerin anormal
proliferasyonu ve inflamatuvar hücre infiltrasyonu ile karakterize
kronik inflamatuvar bir deri hastalığıdır. İnflamatuvar hücre ve
sitokinler hastaların dokuları ile birlikte periferal kanda da tespit
edilmektedir. Bugüne kadar psoriasis vulgariste pek çok inflamatuvar
belirteç bildirilmiştir. Çalışmamızın amacı psoriasisli hastalarda
biyolojik tedavi öncesi ve sonrası nötrofil/lenfosit oranı (NLO),
lenfosit/monosit (LMO), platelet/lenfosit oranı (PLO), RDW/platelet
(RPO) gibi sistemik inflamatuvar belirteçler ile plateletcrit (PCT)’ nin
değişimini araştırmaktır.

Yöntemler: Biyolojik ajanlar ile tedavi edilmiş 42
psoriasis vulgaris hastası geriye dönük olarak değerlendirilmiştir.
Hastaların demografik bilgileri, klinik verileri ve tam kan sayımı
biyolojik tedavinin başlangıcından önce ve tedavi sonrası 3. ayda
değerlendirilmiştir.

Bulgular: Sedimentasyon, C-reaktif protein (CRP),
nötrofil, trombosit, PCT, RDW, NLO ve PLO değerleri tedavi sonrası
tedavi öncesi döneme göre istatistiksel anlamlı olarak azalmıştır
(p<0.05). Ek olarak MPV, PDW, LMR ve RPR sonuçları değerlendirilmiş
tedavi öncesi ve sonrası arasında istatistiksel anlamlı bir fark
bulunamamıştır (p>0.05).

Sonuç: NLO, PLO ve PCT psoriasis vulgaris hastalarının
biyolojik ajan ile tedavi etkinliğinin değerlendirilmesinde bir
belirteç olarak kullanılabilirler.

Anahtar Kelimeler

biy olojik tedavi, biyolojik belirteçler

Kaynakça

• 1. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;94:302-9.
• 2. Hatipoğlu H, Erkal S, Türkmen S, ve ark. Enfeksiyon Hastalıklarının Tanısında Laboratuvar Bulguları. JOPP Derg, 2011;3:5-11.
• 3. Bugada D, Allegri M, Lavand'homme P, et al. Inflammationbased scores: a new meth od for patient targeted strategies and
• improved perioperative outcome in cancer patients. Biomed Res Int. 2014;2014:142425.
• 4. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammationbased prognostic indices in malignant pleural mesothelioma. J Thorac Onc ol. 2012;7:587-94.
• 5. Yamagishi T, Fujimoto N, Nishi H, et al. Prognostic significance of the lymphocytetomonocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90:111-7.
• 6. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72:104-10.
• 7. Kim DS, Shin D, Jee H, et al. Red blood cell distribution widthis increased in patients with psoriasis vulgaris: A retrospective
• study on 261 patients. J Dermatol. 2015;42:567-71.
• 8. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol. 2005;141:1537-41.
• 9. Yamanaka K, Umezawa Y, Yamagiwa A, et al. Biologic therapy improves psoriasis by decreasing the activity of monocytes and
• neutrophils. J Dermatol. 2014;41:679-85.
• 10. Rosman Z, Shoenfeld Y, ZandmanGoddard G. Biologic therapy for autoimmune diseases: an update. BMC Med
• 2013;11:88.
• 11. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19-27.
• 12. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and metaanalysis. Br J Dermatol. 2013;169:266-82.
• 13. RochaPereira P, Santos Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917-28.
• 14. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNFalpha, IFNgamma, IL6, IL8, IL12, IL17, and IL18 in patients
• with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-9.
• 15. Boehncke WH. Perspective: Don't be superficial. Nature. 2012;492:55.
• 16. İlhan M, İlhan G, Gök AF, et al. Evaluation of neutrophillymphocyte ratio, plateletlymphocyte ratio and red blood cell distribution widthplatelet ratio as early predictor of acute pancreatitis in pregnancy. J Matern Fetal Neonatal Med.
• 2016;29:1476-80.
• 17. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ra tio may be predict of mortality in all conditions. Br J Cancer.
• 2013;109:3125–6.
• 18. Imtiaz F, Shafique K, Mirza SS, et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent
• chronic diseases in Asian population. Int Arch Med. 2012;5:2.
• 19. Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed. 2014;26:231-3.
• 20. Orem A, Değer O, Cimşit G, Bahadir S. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta. 1997;264:49-56.
• 21. Zahorec R. Ratio of neutrophil to lymphocyte countsrapid and simple parameter of systemic inflammation and stress in
• critically ill. Bratisl Lek Listy. 2001;102:5-14.
• 22. Demir M. The relationship between neutrophil lymphocyte ratio and nondipper hypertension. Clin Exp Hypertens.
• 2013;35:570-3.
• 23. Boyraz I, Koç B, Boyacı A, et al. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with antiTNF. Int J Clin Exp Med. 2014;7:2912-5.
• 24. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102:653-7.
• 25. Azab B, Jaglall N, Atallah JP, et al. Neutrophillymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis.
• Pancreatology. 2011;11:445-52.
• 26. Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophillymphocyte ratio in ulcerative colitis: a promising marker in
• predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36:491-7.
• 27. Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting longterm mortality after percutane ous coronary intervention. Am J Cardiol. 2006;97:993-6.
• 28. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting shortand longterm mortality after nonSTelevation myocardial infarction. Am J Cardiol. 2010;106:470-76.
• 29. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with STelevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636-42.
• 30. Erturk M, Surgit O, Yalcin AA, et al. The evaluation of relationship between neutrophil tolymphocyte ratio and slow
• coronary flow. Dicle Med J 2013;40:537-42.
• 31. Smith RA, Bosonnet L, Ghaneh P, et al. The platelet lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery. 2008;143:658-66.
• 32. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program.
• 2011;2011:51-61.
• 33. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of allcause mortality after nonSTelevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326-34.
• 34. Kilic E, Rezvani A, Toprak AE, et al.Evaluation of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in
• Rheumatoid Arthritis. Dicle Med J 2016;43:241-7.
• 35. Gunbatar H, Ekin S, Sunnetcioglu A, et al. The relationship between neutrophiltolymphocyte ratio and plateletto lymphocyte ratio in patients with obstructive sleep apnea syndrome. Dicle Med J 2015;42:289-93.
• 36. Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean
• patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43:305-10.
• 37. Kasperska Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets. 2008; 19: 317-21.
• 38. Kim DS, Lee J, Kim SH, et al. Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med J.
• 2015;56:712-8.
• 39. Oylumlu M, Oylumlu M, Yuksel M, et al. The usefulness of plateletcrit to predict cardiac syndrome X in patients with
• normal coronary angiogram. Postepy Kardiol Interwencyjnej. 2015;11:197-201.
• 40. Aynıoglu O, Isık H, Sahbaz A, et al. Can Plateletcrit be a Marker for Recurrent Pregnancy Loss? Clin Appl Thromb
• Hemost. 2016;22:447-52.
• 41. Yurtdaş M, Yaylali YT, Kaya Y, et al. Neutrophilto lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echo cardiography. 2014;31:1095-104.
• 42. Balta I, Balta S, Demirkol S, et al. Neutrophilto lymphocyte ratio may predict subclinical atherosclerosis in patient with
• psoriasis. Echocardiography. 2014;31:1166-7.
• 43. Balta I, Balta S, Demirkol S, et al. Aortic art erial stiffness is a moderate predictor of cardiovascular disease in patients with
• psoriasis vulgaris. Angiology. 2014;65:74-78.
• 44. Nguyen T, Wu JJ. Relationship between tumor necrosis factorα inhibitors and cardiovascular disease in psoriasis: a review. Perm J. 2014;18:49-54.
• 45. Ünal M, Küçük A, Ünal GÜ, et al. Psoriasiste trombosit hacmi, nötrofil/lenfosit trombosit/lenfosit oranı.Türkderm 2015;49:112-6